Quidel

Quidel Acquisitions (Net)

The Acquisitions (Net) of Quidel (QDEL) as of Nov 5, 2026 is 21.70 M USD. In the previous year, Acquisitions (Net) was -26.80 M USD — a change of -180.97% (higher).

Acquisitions (Net)

21.70 MUSD

YoY

-180.97%

Last updated:

Acquisitions (Net) of Quidel is 2023 21.70 M USD. Acquisitions (Net) of Quidel was 2022 -26.80 M USD. It decreases by -180.97% higher compared to the previous year.

The Quidel Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2015
0.00 USD
Jan 1, 2016
-5.10 M USD
Jan 1, 2017
-414.20 M USD
Jan 1, 2018
146.60 M USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
1.60 M USD
Jan 1, 2021
-26.80 M USD
Jan 1, 2023
21.70 M USD
The Quidel Acquisitions (Net) history
YEARAcquisitions (Net)YoY
21.70 MUSD-180.97%
-26.80 MUSD-1,775.00%
1.60 MUSD—
0.00USD-100.00%
146.60 MUSD-135.39%
-414.20 MUSD+8,021.57%
-5.10 MUSD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quidel Stock analysis

What does Quidel do? Quidel Corporation is a US-based company specializing in the production of rapid tests for medical diagnostics. It was founded in 1979 and is headquartered in San Diego, California. Since 1991, it has been listed on the NASDAQ stock exchange. Quidel initially started as Diagnostic Reagents Laboratory (DRL) and focused on manufacturing diagnostic products for the veterinary sector. In 1990, it was renamed Quidel Corporation and expanded its operations into human diagnostics. The company's business model revolves around the development and production of immunological rapid tests that can quickly and easily diagnose infectious diseases and other health problems. Quidel focuses on creating high-quality, accurate, and cost-effective test procedures that can be used by healthcare professionals or even laypersons at home. One of Quidel's core competencies is bringing to market rapid tests that are easy to perform and provide immediate results without the need to send samples to a laboratory. The company offers a wide range of rapid tests for diagnosing various diseases. These include tests for infectious diseases such as influenza, streptococcus, Lyme disease, and chlamydia, as well as tests for pregnancy, drug abuse, and cardiovascular diseases. The tests are available as single tests or panel tests that can diagnose multiple diseases simultaneously. Quidel operates in four business segments: Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassays, and Specialized Diagnostic Solutions. The Molecular Diagnostics segment focuses on developing molecular diagnostic tests and instruments for laboratory use. The Point-of-Care Diagnostics segment develops and produces rapid tests for use in medical practices and hospitals. The Immunoassays segment specializes in reagent-based tests for the quantitative analysis of biomolecules. The Specialized Diagnostic Solutions segment includes specialized diagnostic products, such as test systems for monitoring antibiotic therapies. In conclusion, Quidel Corporation specializes in the development and production of rapid tests for medical diagnostics. The company offers a wide range of high-quality, accurate, and cost-effective test procedures for diagnosing infectious diseases, pregnancy, drug abuse, and cardiovascular diseases. Quidel has gained a significant market share in the diagnostics field through its rapid tests and diverse range of test panels for various conditions, and it is known for its innovative products. Quidel is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quidel stock

Acquisitions (Net) of Quidel is 21.70 M USD in 2023.

Acquisitions (Net) of Quidel changed from -26.80 M USD to 21.70 M USD, representing a -180.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Quidel since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Quidel historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Quidel

All Key Metrics — Quidel